[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508226":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":29,"locations":26,"responsibleParty":39,"collaborators":41,"id":44,"slug":26,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":26,"enrollmentInfo":53,"targetDuration":26,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":26,"overallStatus":63,"whyStopped":26,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":26},{"fullName":5,"class":6},"Hamilton Health Sciences Corporation","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Seizure Prophylaxis (Levetiracetam)","EXPERIMENTAL","Levetiracetam 1 g taken orally twice a day for 7 days",[13],"Drug: Levetiracetam",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo taken orally twice a day for 7 days",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Levetiracetam","Tablets",[9],null,{"type":6,"name":15,"description":24,"armGroupLabels":28,"otherNames":26},[15],[30,36],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Taylor Duda, MD","CONTACT","905-521-2100","44155","taylor.duda@medportal.ca",{"name":37,"role":32,"phone":33,"phoneExt":34,"email":38},"Amanda Martyniuk, MSc","martynia@mcmaster.ca",{"type":40,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[42],{"name":43,"class":6},"McMaster University","100508226",false,"NCT05897658","Levetiracetam Prophylaxis in Brain Tumor Resection Pilot","Pilot Study: Levetiracetam Prophylaxis Randomized Controlled Trial in Brain Tumor Resection","LeviTaTe Pilot","Inclusion Criteria:\n\n* Adult age 18 years or older\n* Undergoing craniotomy for a brain tumor\n* Intra-axial tumor location\n* Supratentorial tumor location\n\nExclusion Criteria:\n\n* Documented seizure history or epilepsy diagnosis\n* Currently taking an antiepileptic medication\n* Unable to take levetiracetam (e.g. allergy, inability to swallow)\n* Inability to obtain consent from participant or substitute decision maker prior to surgery\n* Renal impairment with eGFR less than 50\n* Pregnancy","ALL","18 Years",{"count":54,"type":55},70,"ESTIMATED","INTERVENTIONAL",[58],"PHASE3","This study aims to evaluate feasibility of a double-blind randomized controlled trial for levetiracetam prophylaxis for prevention of seizure in the perioperative phase of brain tumor resection.",[61,62],"Seizures","Brain Tumor","NOT_YET_RECRUITING","2024-10-21",{"date":66,"type":67},"2024-10-23","ACTUAL",{"date":69,"type":55},"2025-03",{"date":71,"type":55},"2026-03",{"name":5,"class":6}]